Blood Affecting Or Blood Protein Utilizing Patents (Class 514/13.5)
  • Patent number: 11325978
    Abstract: The present invention provides new compositions and methods useful for the treatment and potential cure of beta-globinopathies such as sickle cell disease and beta-thalassemia by inhibiting the expression and/or activity of RIOK3.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: May 10, 2022
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: John Fitzgerald Tisdale, Bjorg Gudmundsdottir, Laxminath Tumburu
  • Patent number: 11197916
    Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 14, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kurt Schnecker, Eva Haidweger, Peter Turecek
  • Patent number: 11191813
    Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 7, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kurt Schnecker, Eva Haidweger, Peter Turecek
  • Patent number: 11179484
    Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: November 23, 2021
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Michael K. Schultz, Frances L. Johnson, Somya Kapoor, Dongyoul Lee, Mengshi Li, Molly Martin
  • Patent number: 11147853
    Abstract: Disclosed is a polypeptide binding to a plurality of amyloid monomers and aggregates, characterised in that: the polypeptide contains the amino acid sequences as shown in (a) and/or (b): (a) the general formula of the amino acid sequence is Ser-X1-Phe-X2-Asn-Lys-Arg, wherein X1 and X2 are independently any one of the 20 amino acids; and (b) the variant having the function of the polypeptide and modifying the general formula (a) of the amino acid sequence by the substitution, deletion or addition of one or more amino acid residues.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: October 19, 2021
    Inventors: Ruitian Liu, Xiaolin Yu
  • Patent number: 11083770
    Abstract: A method and medical preparation for enhancing tissue oxygenation by suppression of a hypoxia induced factor 1? (HIF-1?) in case of low oxygen tension in a tissue of a diabetic foot in a patient with type I or type II diabetes mellitus, wherein the method includes administering a dipeptide of L-glutamic acid-L-tryptophan (L-Glu-L-Trp), and wherein the medical preparation includes an effective amount of the dipeptide of L-Glu-L-Trp as an active agent and a pharmaceutically acceptable carrier. Moreover, the method can include administering the medical preparation in a dose of 1.0 ?g per kg-10.0 ?g per kg of body weight at least once a day for a period necessary to achieve a therapeutic effect.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: August 10, 2021
    Assignee: Omnipep Establishment
    Inventors: Aleksandr Vladislavovich Trofimov, Vladimir Khatskelevich Khavinson, Oleg Mikhailovich Ivko, Svetlana Vladislavovna Trofimova
  • Patent number: 11041052
    Abstract: A biodegradable hydrogel having an acetal structure whose hydrolysis rate under different pH environments in the living body can be accurately controlled. The hydrogel is obtained by crosslinking a polyalkylene glycol derivative having a cyclic benzylidene acetal structure represented by formula (1) shown below with a crosslinking agent: where R1 and R6; R2, R3, R4 and R5; s; t; s+t; P1; Z1 and Z2; W1 and X1 are as defined herein.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 22, 2021
    Assignee: NOF CORPORATION
    Inventors: Takuma Tsubusaki, Mika Shishido
  • Patent number: 11026970
    Abstract: Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: June 8, 2021
    Assignee: Hemanext Inc.
    Inventors: Andrew Dunham, Tatsuro Yoshida
  • Patent number: 11000571
    Abstract: An example of the composition incudes at least one amino acid sequence from the octarepeat region of hemin that is modified by substituting at least one proline (P) residue in the amino acid sequence. The composition is effective to bind with hemin and for treating hemorrhagic injury.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: May 11, 2021
    Assignee: Florida State University Research Foundation, Inc.
    Inventor: Ewa Anna Bienkiewicz
  • Patent number: 10994030
    Abstract: A method for measuring, adjusting and maintaining the level of blood volume in a patient is described. A blood volume expander composition includes, in combination, a standard unmodified protein, colloid or crystalloid and a fluorescently-labeled protein, colloid or crystalloid of approximately the same molecular weight. The use of blood volume expanders to measure, adjust and maintain the level of blood volume in a patient also is described.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 4, 2021
    Assignee: PHARMACOPHOTONICS, INC.
    Inventors: Ruben Sandoval, Jr., Erinn Sheridan Reilly, Daniel Meier
  • Patent number: 10927081
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 23, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Patent number: 10918691
    Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: February 16, 2021
    Assignee: RA PHARMACEUTICALS, INC.
    Inventors: Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter
  • Patent number: 10882827
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 5, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C Stephenson, Todd W Seeley, Ingrid Langsetmo Parobok
  • Patent number: 10682394
    Abstract: This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 16, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Atta Behfar, Andre Terzic, Ruben Jose Crespo-Diaz
  • Patent number: 10597432
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: March 24, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10561704
    Abstract: The present invention relates to compositions and methods for treating neuropsychiatric disorders in vertebrates and humans. More specifically, the present invention provides for use of IRL-1620, an endothelin-B receptor agonist, in appropriate doses to be a neuroprotective and a neuroregenerative agent. Accordingly, in one aspect the disclosure provides a method of treating a neuropsychiatric disorder comprising administering to a patient in need thereof a therapeutically effective amount of an endothelin-B receptor agonist to treat the neuropsychiatric disorder. In some embodiments, the endothelin-B receptor agonist is co-administered with an additional agent to treat the neuropsychiatric disorder. In some embodiments, the additional agent is selected from the group consisting of an antidepressant, an anti-inflammatory agent, a CNS stimulant, a neuroleptic, and an anti-proliferative agent.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 18, 2020
    Assignee: MIDWESTERN UNIVERSITY
    Inventor: Anil Gulati
  • Patent number: 10532097
    Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 14, 2020
    Assignee: Academia Sinica
    Inventors: Patrick C. H. Hsieh, Pei-Jung Wu, Steve Roffler, Bill Cheng
  • Patent number: 10279052
    Abstract: A method for measuring, adjusting and maintaining the level of blood volume in a patient is described. A blood volume expander composition includes, in combination, a standard umodified protein, colloid or crystalloid and a fluorescently-labeled protein colloid or crystalloid of approximately the same molecular weight. The use of blood volume expander to measure, adjust and maintain the level of blood volume in a patient also is described.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: May 7, 2019
    Assignee: Pharmacophotonics, Inc.
    Inventors: Ruben Sandoval, Jr., Erinn Sheridan Reilly, Daniel Meier
  • Patent number: 10080782
    Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: September 25, 2018
    Assignee: Prolong Pharmaceuticals, LLC
    Inventors: Abraham Abuchowski, Steven Sloshberg, Keith O'Hare
  • Patent number: 10047142
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 14, 2018
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Patent number: 9782452
    Abstract: This disclosure demonstrates that blockade of TGF? signaling after a hematopoietic stress (e.g., chemotherapy, transplantation, and infection) accelerates hematopoietic reconstitution and delays the return of cycling hematopoietic stem and progenitor cells (HSPCs) to quiescence. TGF? blockade in these settings promotes multilineage hematopoietic regeneration by prolonging HSPC cycling and by promoting HSC self-renewal, and is useful for treating hematologic deficiencies caused various hematopoietic stresses.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: October 10, 2017
    Assignee: Cornell University
    Inventors: Joseph Scandura, Fabienne Brenet
  • Patent number: 9775853
    Abstract: Compositions and methods for achieving hemostasis. Hemostatic compositions comprise a phospholipid, and optionally, an anti-infective agent. The hemostatic composition can be administered to a bleeding bone to achieve hemostasis.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 3, 2017
    Assignee: Biomet Manufacturing, LLC.
    Inventors: Karen S. Troxel, Michael Ponticiello
  • Patent number: 9644197
    Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: May 9, 2017
    Assignee: SK Chemicals Co., Ltd.
    Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim
  • Patent number: 9629909
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: April 25, 2017
    Assignee: Domantis Limited
    Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Patent number: 9493507
    Abstract: Use of synthetic thiol-containing peptides as highly effective therapeutic and protective agents is described, in clinical and research applications where lifespan and/or viability and functioning of cells is compromised at least partially due to depletion of reduced glutathione, or where viability and functioning of cells can be improved by elevating reduced glutathione levels. More specifically, compositions and methods for treating blood disorders associated with glutathione dysregulation utilizing short thiol-containing peptides selected from the group consisting of Cys-Lys-Met-Cys (SEQ ID NO: 1), Cys-Met-Lys-Cys (SEQ ID NO: 2) and Cys-?-Ala-His-Cys (SEQ ID NO: 3) are described. Further described are compositions and methods for preserving biological samples using the peptides.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 15, 2016
    Assignee: ONEDAY—BIOTECH AND PHARMA LTD.
    Inventor: Josef Mograbi
  • Patent number: 9428552
    Abstract: Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2) or Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3) effective to mobilize the stem cells. This is useful for promoting bodily tissue regeneration in a patient in need of tissue regeneration treatment. Alternatively, the mobilized stem cells can be collected for transplant.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: August 30, 2016
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Irena Tsyrlova, Fawn Petty, Reid W. von Borstel, Julian Reading, Jiong Pei, Joel Saydoff
  • Patent number: 9272021
    Abstract: The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: March 1, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Friedrich Scheiflinger, Peter Turecek, Bruce Ewenstein, Wing Yen Wong, Tobias M. Suiter
  • Patent number: 9138464
    Abstract: The present invention relates to compositions for delivering nitric oxide (NO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver NO to cells.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: September 22, 2015
    Inventors: Robert M. Winslow, Kim D. Vandergriff, Nancy Jo Winslow
  • Publication number: 20150148296
    Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 28, 2015
    Applicants: ASAHI KASEI PHARMA CORPORATION, KINKI UNIVERSITY
    Inventors: Atsufumi Kawabata, Hideaki Suzuki
  • Publication number: 20150141341
    Abstract: Methods and compositions for the treatment of ?-thalassemia are provided. Methods and compositions restore or increase erythrocyte maturation in individuals afflicted with ?-TM by preventing proteolysis of GATA-1 protein. Screening methods for identifying agents which bind heat shock protein 70 (HSP-70) and inhibit HSP-70 ?-globin binding, but which allow GATA-1 protein-HSP-1 binding in a manner that prevents GATA-1 proteolysis.
    Type: Application
    Filed: November 19, 2014
    Publication date: May 21, 2015
    Inventors: Olivier HERMINE, Genevieve COURTOIS, Jean-Benoit ARLET, Jean-Antoine RIBEIL
  • Publication number: 20150133386
    Abstract: Compositions and methods for treating blood disorders associated with glutathione dysregulation, utilizing short thiol-containing peptides selected from the group consisting of Cys-Lys-Met-Cys (SEQ ID NO: 1), Cys-Met-Lys-Cys (SEQ ID NO: 2) and Cys-?-Ala-His-Cys (SEQ ID NO: 3). Compositions and methods for preserving biological samples using the peptides. Use of synthetic thiol-containing peptides as highly effective therapeutic and protective agents in clinical and research applications where lifespan and/or viability and functioning of cells is compromised at least partially due to depletion of reduced glutathione, or where viability and functioning of cells can be improved by elevating reduced glutathione levels.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventor: Josef Mograbi
  • Publication number: 20150132362
    Abstract: The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.
    Type: Application
    Filed: September 8, 2014
    Publication date: May 14, 2015
    Inventors: Joris Hoefinghoff, Hans Christian Hedrich
  • Patent number: 9023992
    Abstract: The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Daniel E. Rasmussen, Janus Krarup
  • Publication number: 20150119331
    Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Applicant: Symbiotec Genellschaft zur Erforshung auf dem Geibeit der Biotechnologie, MBH
    Inventors: Michael Zeppezauer, Reiner Class
  • Publication number: 20150104445
    Abstract: Methods and compositions are provided for treating diseases implicating alternative pathway complement immune system activation.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventors: Marc E. Uknis, Jo Anne M. Saye, Colin Broom
  • Patent number: 8999297
    Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: April 7, 2015
    Assignee: Inter-Med, Inc.
    Inventors: Gary J. Pond, John Baeten
  • Patent number: 8999333
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: April 7, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Publication number: 20150094268
    Abstract: The present invention provides a prophylactic or therapeutic agent for a hepatic disease, containing AIM or a partial peptide thereof, or a nucleic acid containing a base sequence encoding the same, a method of screening for a prophylactic or therapeutic agent for a hepatic disease, comprising using an0 animal obtained by loading a non-human mammal deficient in AIM expression with a high fat diet and the like.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 2, 2015
    Inventor: Toru Miyazaki
  • Publication number: 20150087591
    Abstract: The present invention provides a safe, reliable, and economical process for preparing an improved dialysis fluid formulation effective for extracorporeal treatment, through a blood filtration process, of a Beta-Amyloid associated pathological condition in a subject, said process comprises preparing a composition comprising KLVFF peptide, or a variant thereof, as the capturing and binding agent, and a carrier therefor, and mixing said composition with a dialysate solution. The process utilizes a compact, inexpensive, and simple standard dialysis machine that extracorporeally removes Beta-Amyloids without allowing escape of the Beta-Amyloids back into a subject's body, without having to intricately evaluate the performance and characteristics of a dialysis membrane, and without putting the health condition of the subject at risk.
    Type: Application
    Filed: January 30, 2013
    Publication date: March 26, 2015
    Applicant: Amylex Pharmaceuticals, Inc.
    Inventors: Chinnaswamy Kasinathan, Rogelio B. Santos, JR., Stanley Stein
  • Publication number: 20150087592
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Applicant: CSL Behring GmbH
    Inventors: Stefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr
  • Patent number: 8987190
    Abstract: The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated erythropoietin.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: March 24, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Nikolaj Sager, Michael Chopp, Zheng Gang Zhang
  • Patent number: 8969299
    Abstract: Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: March 3, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Gregory Bell
  • Patent number: 8962562
    Abstract: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: February 24, 2015
    Assignee: Lipoxen Technologies Incorporated
    Inventors: Reiner Class, Michael Zeppezauer
  • Publication number: 20150044166
    Abstract: Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (EIPH) and nasopharyngeal cicatrix (NC) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors. Exemplary stem cell derived factors include, but are not limited to, growth factors, chemokines, and cytokines. The mammal may be a horse, dog, camel, or Homo sapiens.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 12, 2015
    Inventor: Michael Riddle, JR.
  • Patent number: 8946161
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 3, 2015
    Assignee: Ratiopharm GmbH
    Inventors: Walter Hinderer, Heinz Lubenau
  • Patent number: 8945895
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Patent number: 8946160
    Abstract: Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: February 3, 2015
    Assignee: Oral Delivery Technology Ltd.
    Inventor: Michael Farber
  • Publication number: 20150031618
    Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.
    Type: Application
    Filed: January 31, 2013
    Publication date: January 29, 2015
    Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
  • Publication number: 20150023949
    Abstract: Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 22, 2015
    Inventors: Niven Rajin Narain, Paula Patricia Narain
  • Publication number: 20150017146
    Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.
    Type: Application
    Filed: August 7, 2014
    Publication date: January 15, 2015
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Seetharama A. Acharya, Marcos Intaglietta